-20C, 1 month (sealed storage, away from moisture and light, under nitrogen)
As of a January 2026 legal analysis, BPC-157 remained listed in Category 2, and the compound cannot legally be compounded under sections 503A or 503B of the Food, Drug and Cosmetic Act
While NAD therapy shows promise in several areas, we emphasize that more clinical research is needed to fully understand its benefits, risks, and best practices
Fernandes Gomes B, Kumar A, Ashton NJ et al (2024) Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders
Handle with appropriate laboratory safety protocols
T cells mature there, acquire the ability to recognize novel threats, and graduate into circulation equipped to respond to things the body has never encountered before